The prothrombotic fibrin clot phenotype has been reported in patients with thrombotic
antiphospholipid syndrome (APS) and venous thromboembolism (VTE). Protein composition …

We tested the hypothesis that plasma fibrin clot structure/function is unfavourably altered in
patients with antiphospholipid syndrome (APS). Ex vivo plasma clot permeability, turbidity …

Background Antiphosphatidylserine/prothrombin complex (aPS/PT) antibodies are
recognized as a marker for antiphospholipid syndrome (APS). Dense and poorly lysable …

Objective The antiphospholipid syndrome (APS) is defined by persistent antiphospholipid
antibodies together with thrombosis and/or pregnancy morbidity. We investigated the …

Objectives APS is associated with arterial and venous thrombosis. The unfavourable fibrin
clot phenotype, including formation of dense and poorly lysable clots, has been reported in …

Introduction Formation of denser fibrin networks displaying impaired lysability has been
reported in subjects at an increased risk of atherosclerosis. Given recent data on …

Monitoring warfarin anticoagulation in patients with thrombotic antiphospholipid syndrome
(APS) may be complicated by the sensitivity of different thromboplastins to lupus …

The antiphospholipid syndrome (APS) is characterised by both arterial and venous
thrombosis, recurrent pregnancy loss and thrombocytopaenia in association with …

A reduction in fibrinolysis has been described in association with thrombosis in the primary
antiphospholipid syndrome (PAPS). In this study, we measured anti‐tissue‐type …

Background Thrombosis and complement activation are pathogenic features of
antiphospholipid syndrome (APS). Their molecular link is Plasma carboxypeptidase-B, also …